Disagree
Home Driada Medical Driada Medical
Cialyn 5
Cialyn 5 - Driada Medical

Cialyn 5 - Driada Medical

Brand:
Category:
Substance:
Dosage:
5 mg/tab
Package:
20 tablets
Price:
0
See options
Product Overview
Tadalafil, marketed as Cialis, was developed by ICOS Corporation in the early 1990s and gained FDA approval in 2003. Initially studied for cardiovascular uses, its potential for treating erectile dysfunction (ED) led to its reclassification. With a half-life of 17.5 hours, tadalafil offers up to 36 hours of efficacy—significantly longer than other PDE5 inhibitors like sildenafil. Its unique structure and once-daily dosing option give patients greater flexibility, making it a preferred choice for men seeking both spontaneity and long-term management of ED.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Cialyn 5 by Driada Medical, consult with your doctor or healthcare professional.

Explore More Products
FAQ
When was Tadalafil citrate developed?
Tadalafil citrate was developed in the late 1990s during competitive research into PDE5 inhibitors.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

Does Tadalafil citrate belong to the same chemical class as sildenafil?
No, although both are PDE5 inhibitors, Tadalafil citrate is structurally a β-carboline compound, unlike sildenafil.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.

What advantage does once-daily Tadalafil citrate offer?
It maintains steady blood levels, eliminating the need to plan dosing around sexual activity.
References:

Coward, R.M. & Carson, C.C., 2008. Tadalafil in the treatment of erectile dysfunction. Therapeutics and Clinical Risk Management.